| Literature DB >> 27456841 |
Kim G Jackson1,2, Yue Li1,2, Miriam F Ryan3, Eileen R Gibney3, Lorraine Brennan3, Helen M Roche3, Christine M Williams2, Julie A Lovegrove1,2, Karani S Vimaleswaran4,5.
Abstract
BACKGROUND: Reported associations between Tumor Necrosis Factor-alpha (TNFA) and the postprandial triacylglycerol (TAG) response have been inconsistent, which could be due to variations in the TNFA gene, meal fat composition or participant's body weight. Hence, we investigated the association of TNFA polymorphism (-308G → A) with body mass index (BMI) and postprandial lipaemia and also determined the impact of BMI on the association of the polymorphism with postprandial lipaemia.Entities:
Keywords: BMI; MECHE; Postprandial lipaemia; TNFA promoter polymorphism; Triacylglycerol
Mesh:
Substances:
Year: 2016 PMID: 27456841 PMCID: PMC4960705 DOI: 10.1186/s12937-016-0190-9
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Fasting and postprandial metabolites and characteristics according to the TNFA-380G → A polymorphism stratified by body mass index in the UK postprandial cohort
| Normal weight (BMI < 25 kg/m2) | Overweight/obese (BMI ≥ 25 kg/m2) |
| |||||
|---|---|---|---|---|---|---|---|
| GG ( | GA + AA ( |
| GG ( | GA + AA ( |
| ||
| Age (yrs) | 51 ± 2 | 48 ± 2 | 0.16 | 54 ± 1 | 54 ± 2 | 0.96 | 0.09 |
| Gender (men/women) | 24/32 | 10/28 | 0.10 | 70/38 | 18/10 | 0.96 | 0.03 |
| BMI (kg/m2)b | 23.10 ± 0.20 | 23.20 ± 0.20 | 0.21 | 28.50 ± 0.20 | 28.00 ± 0.30 | 0.29 | 0.03 |
|
| |||||||
| TC (mmol/l) | 5.46 + 0.13 | 5.30 ± 0.15 | 0.97 | 5.81 ± 0.10 | 5.85 ± 0.21 | 0.89 | 0.97 |
| TAG (mmol/l) | 1.27 ± 0.70 | 1.11 ± 0.07 | 0.43 | 1.81 ± 0.09 | 1.65 ± 0.11 | 0.36 | 0.23 |
| HDL-c (mmol/l) | 1.48 ± 0.05 | 1.56 ± 0.07 | 0.73 | 1.24 ± 0.04 | 1.31 ± 0.06 | 0.37 | 0.54 |
| LDL-c (mmol/l) | 3.39 ± 0.13 | 3.27 ± 0.15 | 0.79 | 3.76 ± 0.09 | 3.79 ± 0.20 | 0.89 | 0.81 |
| Glucose (mmol/l) | 4.98 ± 0.07 | 4.78 ± 0.06 | 0.31 | 5.37 ± 0.07 | 4.99 ± 0.09 | 0.007 | 0.006 |
| Insulin (pmol/l)c | 36.50 ± 3.70 | 32.00 ± 4.30 | 0.51 | 57.60 ± 3.80 | 49.20 ± 6.60 | 0.75 | 0.54 |
| NEFA (μmol/l) | 525 ± 30 | 493 ± 26 | 0.39 | 526 ± 17 | 494 ± 39 | 0.59 | 0.39 |
| HOMA-IRc | 1.40 ± 0.20 | 1.20 ± 0.20 | 0.43 | 2.40 ± 0.20 | 2.00 ± 0.30 | 0.62 | 0.44 |
|
| |||||||
| TAG (mmol/l × 480 min) | |||||||
| AUC | 885 ± 51 | 754 ± 44 | 0.42 | 1293 ± 55 | 1189 ± 78 | 0.31 | 0.15 |
| IAUCd | 284 ± 26 | 191 ± 21 | 0.09 | 396 ± 24 | 333 ± 29 | 0.12 | 0.02 |
| NEFA (mmol/l × 300 min)e | |||||||
| AUC | 147 ± 8 | 140 ± 7 | 0.35 | 157 ± 5 | 163 ± 7 | 0.29 | 0.92 |
| IAUC | 92 ± 6 | 70 ± 16 | 0.06 | 102 ± 3 | 110 ± 6 | 0.22 | 0.49 |
| Glucose (mmol/l × 480 min)f | |||||||
| AUC | 2943 ± 45 | 2740 ± 166 | 0.46 | 3176 ± 56 | 2968 ± 153 | 0.15 | 0.07 |
| IAUC | 564 ± 45 | 514 ± 55 | 0.82 | 590 ± 32 | 603 ± 60 | 1.00 | 0.93 |
| Insulin (nmol/l × 480 min)g | |||||||
| AUC | 99 ± 11 | 117 ± 9 | 0.37 | 141 ± 19 | 149 ± 30 | 0.28 | 0.33 |
| IAUC | 81 ± 9 | 99 ± 9 | 0.41 | 129 ± 17 | 122 ± 28 | 0.47 | 0.36 |
Values represent mean ± S.E. mean
As the AA homozygotes were rare (1.7 %), all analyses were conducted by comparing GG homozygotes A allele carriers (GA + AA)
Abbreviations: AUC, area under the curve, BMI body mass index, HDL-c high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, IAUC incremental area under the curve, LDL-c low density lipoprotein cholesterol, NEFA non-esterified fatty acids, TAG triacylglycerol, TC total cholesterol
aAdjusted for age, gender, and body mass index
bAdjusted for age, and gender
cBMI < 25, GG (N = 34), A (N = 19); BMI ≥ 25, GG (N = 79), A (N = 19)
dBMI < 25, GG (N = 56), A (N = 37); BMI ≥ 25, GG (N = 106), A (N = 26)
eBMI < 25, GG (N = 36), A (N = 19); BMI ≥ 25, GG (N = 84), A (N = 21)
fBMI < 25, GG (N = 36), A (N = 20); BMI ≥ 25, GG (N = 86), A (N = 22)
gBMI < 25, GG (N = 15), A (N = 7); BMI ≥ 25, GG (N = 35), A (N = 10)
* P values for the difference in the clinical and biochemical parameters between the genotypes in the whole group
Fig. 1Incremental triacylglycerol response (mmol/l) according to the TNFA −308 G/A polymorphism. Mean (SEM) for the incremental triacylglycerol response (mmol/l) according to the TNFA −308 G/A polymorphism [GG genotype (N = 162), open squares and GA + AA genotype combination (N = 64, open circles)] after consumption of a test breakfast (49 g fat) at 0 min and a test lunch (29 g fat) at 330 min. P value represents the difference in the incremental triacylglycerol response between the genotypes (GG vs. GA + AA) of the TNFA −308 G/A polymorphism
Fasting and postprandial metabolites and characteristics according to the TNFA-380G → A polymorphism stratified by body mass index in the Metabolic Challenge Study (Replication cohort)
| Normal weight (BMI <25 kg/m2) | Overweight/obese (BMI ≥ 25 kg/m2) |
| |||||
|---|---|---|---|---|---|---|---|
| GG ( | GA + AA ( |
| GG ( | GA + AA ( |
| ||
| Age | 31 ± 2 | 27 ± 3 | 0.34 | 31 ± 2 | 35 ± 4 | 0.29 | 0.74 |
| Gender (men/women) | 8/22 | 8/7 | 0.08 | 10/4 | 4/4 | 0.32 | 0.38 |
| BMI (kg/m2)b | 22.70 ± 0.30 | 22.40 ± 0.50 | 0.52 | 26.80 ± 0.60 | 26.70 ± 0.50 | 0.85 | 0.58 |
|
| |||||||
| TC (mmol/l) | 4.50 ± 0.20 | 4.30 ± 0.20 | 0.88 | 4.30 ± 0.20 | 5.10 ± 0.30 | 0.04 | 0.48 |
| TAG (mmol/l) | 0.94 ± 0.07 | 0.86 ± 0.05 | 0.48 | 1.18 ± 0.2 | 1.30 ± 0.20 | 0.72 | 0.97 |
| Glucose (mmol/l) | 5.01 ± 0.08 | 5.20 ± 0.10 | 0.26 | 5.30 ± 0.10 | 5.30 ± 0.08 | 0.93 | 0.46 |
| HDL-c (mmol/l) | 1.50 ± 0.07 | 1.40 ± 0.09 | 0.95 | 1.20 ± 0.08 | 1.40 ± 0.20 | 0.33 | 0.79 |
| Insulin (pmol/l) | 34.80 ± 0.60 | 36.10 ± 4.90 | 0.71 | 43.80 ± 5.60 | 50.70 ± 6.30 | 0.49 | 0.23 |
| NEFA (μmol/l) | 590 ± 50 | 590 ± 90 | 0.73 | 560 ± 29 | 550 ± 25 | 0.69 | 0.99 |
| HOMA-IR | 2.00 ± 0.20 | 2.10 ± 0.30 | 0.69 | 2.50 ± 0.40 | 2.80 ± 0.30 | 0.59 | 0.27 |
| TNFA (pg/ml) | 10.20 ± 4.50 | 4.30 ± 1.80 | 0.59 | 4.10 ± 0.40 | 4.70 ± 0.70 | 0.35 | 0.45 |
|
| |||||||
| AUC | 176 ± 31 | 170 ± 41 | 0.74 | 184 ± 50 | 192 ± 66 | 0.78 | 0.99 |
| IAUC | 81 ± 15 | 84 ± 23 | 0.87 | 63 ± 26 | 81 ± 28 | 0.54 | 0.72 |
|
| |||||||
| AUC | 39 ± 7 | 36 ± 8 | 0.73 | 26 ± 7 | 32 ± 10 | 0.58 | 0.96 |
| IAUC | 14 ± 3 | 12 ± 4 | 0.44 | 6 ± 2 | 3 ± 5 | 0.18 | 0.65 |
|
| |||||||
| AUC | 483 ± 75 | 485 ± 108 | 0.89 | 468 ± 108 | 442 ± 713 | 0.95 | 0.98 |
| IAUC | −23 ± 9 | −31 ± 12 | 0.47 | −72 ± 36 | −9 ± 6 | 0.21 | 0.34 |
|
| |||||||
| AUC | 4209 ± 806 | 4223 ± 1035 | 0.71 | 6257 ± 2368 | 5382 ± 1792 | 0.73 | 0.82 |
| IAUC | 986 ± 340 | 313 ± 465 | 0.11 | 2417 ± 1695 | 1063 ± 597 | 0.46 | 0.28 |
Values represent mean ± S.E. mean
As there was only one participant with AA homozygous genotype, all analyses were conducted by comparing GG homozygotes and A allele carriers (GA + AA)
Abbreviations: AUC area under the curve, IAUC, incremental area under the curve, BMI body mass index, TAG triacylglycerol, TC total cholesterol, HDL-c high density lipoprotein cholesterol
aAdjusted for age, gender, and BMI, wherever appropriate
bAdjusted for age, and gender
* P values for the difference in the clinical and biochemical parameters between the genotypes in the whole group